Raymond James raised the firm’s price target on Omega Healthcare (OHI) to $46 from $42 and keeps an Outperform rating on the shares. The recession-resilient and defensive, needs-driven nature of healthcare is increasingly top of mind in the current uncertain environment, the analyst tells investors in a research note. Improving operator fundamentals, an accommodative cost of capital and capacity for accretive external growth, remain attractive attributes of Omega, the firm says.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare price target raised to $42 from $39 at Scotiabank
- MedaSync announces strategic investment from Omega Healthcare
- Omega Healthcare Investors Reports Strong Q2 2025 Results
- Omega Healthcare Investors’ Earnings Call Highlights Robust Growth
- Omega Healthcare’s Strong Q2 Performance and Strategic Moves Justify Buy Rating
